Loading clinical trials...
Loading clinical trials...
Phase 1b Study of Extended Dosing of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer.
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Winthrop University Hospital
Mineola, New York, United States
Lenox Hill Hospital
New York, New York, United States
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
August 23, 2013
Primary Completion Date
September 8, 2016
Completion Date
September 9, 2019
Last Updated
June 18, 2021
37
ACTUAL participants
DPX-Survivac
BIOLOGICAL
DPX-Survivac(Aqueous)
BIOLOGICAL
Cyclophosphamide
DRUG
Lead Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT04657068
NCT05281471
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions